- Aust Prescr 2004;27:76-9
- 1 June 2004
- DOI: 10.18773/austprescr.2004.066
23.75 mg, 47.5 mg, 95 mg and 190 mg controlled-release tablets
Approved indication: chronic heart failure
Australian Medicines Handbook section 6.4.3
Beta blockers used to be contraindicated in heart failure, but they can benefit some patients with chronic stable heart failure.1 A placebo-controlled study of 3991 patients who were already on optimum therapy, such as a diuretic and an ACE inhibitor, found that metoprolol significantly reduced deaths. After a year the mortality rate was 7.2%in the metoprolol group and 11% in the placebo group.2
The preparation used in the clinical trial was an extended-release formulation. This contained metoprolol succinate as opposed tometoprolol tartrate which is used in the treatment of angina and hypertension.
The two salts of metoprolol have been compared in a haemodynamic study. This found that both salts had similar effects.3The extended-release formulation is given once a day. Its peak plasma concentrations are only 25% or 50% of those of the conventional formulation, but they produce comparable beta blockade over 24 hours.
When the extended-release tablets are prescribed for heart failure, the dose must be slowly increased over several weeks. If the heart failure gets worse during this titration metoprolol succinate may need to be discontinued.
† At the time the comment was prepared, a scientific discussion about this drug was available on the web site of the European Agency for the Evaluation of Medicinal Products (www.emea.eu.int).